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ABSTRACT
Introduction: Psoriatic arthritis (PsA) is
underdiagnosed and has a substantial impact
on quality of life, disability, and work
productivity. The population-based
Multinational Assessment of Psoriasis and
Psoriatic Arthritis (MAPP) survey examined the
impact of PsA on patients’ activities of daily
living and unmet treatment needs.
Methods: This large-scale, random digit dialing,
telephone survey of patients self-reporting a
diagnosis of psoriasis and/or PsA was conducted
in North America and Europe.
Results: In all, 3426 patients participated in the
survey, including 712 (21%) who identified
themselves as having PsA. Over half of the
patients reported severe PsA involving more
than four joints. Eighty-three percent of
patients with PsA visited a health-care provider
within the past 12 months. Approximately
one-quarter saw their primary care provider or
dermatologist most often for their disease; 37%
responded that their rheumatologist was the
health-care provider seen most often for PsA.
Patients with PsA reported a substantial impact
of disease on physical function. One-third of
patients with PsA reported missing work
because of their disease and PsA impacted
their ability to work full time. Over half of the
patients with PsA (58%) reported receiving no
treatment or topical therapy only, leaving their
joint disease untreated. Factors associated with
lack of adherence were perceived lack of efficacy
and concerns about long-term safety.
Conclusions: The MAPP survey confirms that
PsA has a significant impact on physical
function and activities of daily living.
Undertreatment of PsA suggests a need for
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improved screening and diagnosis as well as
education about treatment options and
adherence.
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INTRODUCTION
Psoriatic arthritis (PsA) is a chronic, systemic
inflammatory disease, with symptoms that
typically include swelling and pain in the
peripheral joints, enthesitis, and dactylitis. The
clinical presentation of PsA varies. It occurs in
approximately 30% of patients with psoriasis [4,
12, 16, 25, 28] and typically follows the onset of
psoriasis by approximately 8–10 years [12, 22].
Nail involvement typically occurs more often
and is more severe in patients with PsA than in
those with psoriasis alone and may predict the
development of PsA in patients with psoriasis
[10, 12, 16, 20, 24, 30, 35].
The burden of ongoing skin and joint
inflammation characteristic of PsA is often
overwhelming. In particular, the disease
negatively affects quality of life (QoL) and
work productivity, and leads to high rates of
health-care utilization [4, 24, 32, 33]. Patients
with PsA report reduced QoL and have more
work-related problems, health-care visits, and
hospitalizations than patients with psoriasis
alone [4]. The progression of joint disease is
associated with greater disability, and QoL
sharply declines as limitations in daily
activities increase [24, 32]. Likewise, PsA is
associated with increased medical costs and
loss of work productivity as the level of
severity increases [4]. In addition, evidence
suggests that persistent systemic inflammation
fosters and worsens the severity of other
co-morbidities, such as obesity and heart
disease [4, 6, 11, 15].
The Multinational Assessment of Psoriasis
and Psoriatic Arthritis (MAPP), a
population-based survey of 3426 patients and
nearly 781 physicians in North America and
Europe, is the largest probability survey of
psoriatic disease conducted to date [22, 23,
34]. Here, we explore the results compiled from
the subset of patients with PsA participating in
the MAPP survey. We hypothesized that PsA
would have a substantial impact on disease
burden in the subset of patients with PsA in the
MAPP survey.
METHODS
Abt SRBI, Inc. (New York, NY, USA) conducted
the MAPP survey between June and August
2012 [22]. Via telephone, Abt SRBI staff
surveyed households in the USA, Canada,
France, Germany, Italy, Spain, and the UK.
The MAPP survey followed the American
Association for Public Opinion Research
guidelines for developing and conducting
surveys [1]. Institutional review board approval
was granted for data collection in the USA (Abt
SRBI 5454), and the other countries abided by
standards and ethical practices according to
their codes or guidelines.
Random digit dialing was performed to
provide a probability sample, and participants
were invited to complete the survey if they were
C18 years of age and were ever diagnosed with
psoriasis and/or PsA by a health-care provider
(HCP). The survey questions used have been
published previously [22] and included
questions regarding types and severity of
psoriasis and/or PsA symptoms, factors
contributing to the severity of disease, if and
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how psoriasis and/or PsA affects activities of
daily living and work, interactions with HCPs
for psoriasis and/or PsA, current and prior
treatments, and factors affecting the choice of
treatments.
Survey questions related to joint symptoms
and physical function are provided in Table 1.
RESULTS
Patients and Disease History
A total of 139,948 households were screened,
and 3426 patients agreed to participate in the
MAPP survey. Of the overall MAPP patient
population, 712 respondents (21%) reported a
diagnosis of PsA. The mean age of the patients
with PsA was 56 years, the majority were female,
and nearly three-quarters reported being
overweight (33.6%) or obese (36.4%; Table 2).
Co-morbidities were common in patients with
PsA, with arthritis (unspecified), hypertension,
depression, diabetes, and heart disease reported
most often. The average age of patients at the
time of PsA diagnosis was 42 years, with an
average delay between the onset of joint
symptoms and diagnosis of PsA of 5 years.
Most patients with PsA (72%) developed skin
signs and symptoms first, but 21% reported that
they had joint signs and symptoms first, and 7%
reported that skin and joint signs and
symptoms appeared concurrently. PsA was
diagnosed on average 8 years after psoriasis;
27% of the surveyed patients reported that they
were diagnosed with psoriasis and PsA at the
same time.
Table 1 Survey questions related to joint count and physical function
Do you have pain or soreness in any of your joints?
How many joints are affected?
Where (body location) is the joint pain (or soreness) most bothersome?
Do you have ‘‘sausage’’ digits (pain or swelling of an entire ﬁnger[s])?
Do you have pain or swelling of the heel?
On a scale of 1–10, where ‘‘1’’ is ‘‘very mild’’ and ‘‘10’’ is ‘‘very severe,’’ how would you rate the severity of your (psoriasis/
psoriatic arthritis) at its WORST?
What is the MOST important factor which contributes to the severity of your disease?
At this moment, are you able to
Dress yourself, including tying shoelaces and doing buttons?
Get in and out of bed?
Lift a full cup or glass to your mouth?
Walk outdoors on ﬂat ground?
Wash and dry your entire body?
Bend down to pick up clothing from the ﬂoor?
Turn faucets on and off?
Get in and out of the car?
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Current Symptoms
At the time of the survey, 88% of patients
reported current joint pain or soreness; of these,
60% reported that more than four joints were
affected (Fig. 1a). Of the patients reporting joint
pain, 41% had knee pain, 26% had finger pain,
19% had hip pain, 19% had ankle pain, 18%
had back pain, and 16% had wrist pain. In all,
31% of patients reported symptoms resembling
enthesitis (i.e., pain/swelling of heel), and 45%
reported symptoms resembling dactylitis (i.e.,
having ‘‘sausage’’ digits). In addition, patients
reported itching (62%), scales (58%), flaking
(58%), redness (58%), and pain (51%) associated
with psoriasis lesions. Nail symptoms were
present in nearly twice as many patients with
PsA (21%) compared with patients with
psoriasis alone (11%). Scalp involvement was
reported by 44% of patients with PsA and 48%
with psoriasis alone.
Self-perceived Severity
Patients were asked to rate their disease severity
at its worst on a scale of 1 (very mild) to 10 (very
severe). More than half of the patients with PsA
(53%) rated their disease as severe (score: 8–10),
35% rated their disease as moderate (score: 4–7),
and 12% rated their disease as mild (score: 1–3;
Fig. 1b). In comparison, 27% of psoriasis
patients rated their disease as severe [22]. As
expected, the most important factor affecting
self-perceived severity in patients with PsA was
pain or swelling of the joints (45%); other
commonly reported factors included itching
(18%), location and size of skin lesions (10%),
and lack of sleep (7%).
Impact on Physical Function: the HAQ-8
The proportions of PsA patients answering
‘‘with much difficulty’’ or ‘‘unable to do’’ on
the eight-item Health Assessment
Questionnaire (HAQ-8 or modified HAQ [27])
progressively increased for those with more
than four affected joints and those with
symptoms resembling enthesitis or dactylitis;
Table 2 Baseline demographics of patients diagnosed with
PsA
Demographics PsA patients
N5 712
Age (years)
Mean (median) 56 (56)
Range 18–93
Male, n (%) 280 (39.3)
Body mass index (kg/m2), n (%)
Underweight (\18.5) 8 (1.1)
Normal (18.5–24.9) 168 (23.6)
Overweight (25.0–29.9) 239 (33.6)
Obese (C30) 259 (36.4)
Co-morbidities, n (%)
Arthritis 388 (54.5)
Cancer 52 (7.3)
Crohn’s disease 22 (3.1)
Diabetes 129 (18.1)
Depression 197 (27.7)
Hypertension 293 (41.2)
Heart disease 105 (14.7)
Liver disease 22 (3.1)
Ulcerative colitis 33 (4.6)
Uveitis 15 (2.1)
Other 56 (7.9)
None 128 (18.0)
Data are weighted based on the population prevalence of
psoriasis and PsA and the overall population within each
country
PsA psoriatic arthritis
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patients with enthesitis or dactylitis reported
the most disability on all items of the HAQ-8
(Fig. 2a). Likewise, the proportions of patients
with PsA answering ‘‘with much difficulty’’ or
‘‘unable to do’’ increased for most questions in
patients with higher palm counts (Fig. 2b),
Fig. 1 Number of
affected joints (a) and
self-assessed severity
(b) in patients with
PsA. aIncludes only
patients with PsA
who reported joint
pain (n = 628). PsA
pssoriatic arthritis
Fig. 2 Impact of PsA
on the 8-item Health
Assessment
Questionnaire and the
proportion of patients
responding ‘‘with
much difﬁculty’’ or
‘‘unable to do’’ (a),
and impact of
psoriasis palm count
on the 8-item Health
Assessment
Questionnaire in
patients with PsA and
the proportion of
patients responding
‘‘with much difﬁculty’’
or ‘‘unable to do’’ (b).
PsA psoriatic arthritis
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suggesting that skin disease also contributes to
disability.
Employment Status and Work Impact
PsA severely impacted patients’ work
productivity (Fig. 3). Nearly one-third of
patients with PsA (31.5%) reported that they
had missed work in the past 12 months because
of their disease. Similarly, 31.6% reported that
PsA had impacted their ability to work full time.
Approximately one-quarter of patients with PsA
reported ‘‘a lot’’ or ‘‘some’’ impact of their
disease on getting a job, keeping a job, and
choice of career. These results are consistent
with survey results of patients with psoriasis,
which found that patients with psoriasis were
significantly more likely to miss work time and
to experience impairment while working
compared with controls [36].
Medical Care and Treatment
In all, 83% of patients visited an HCP in the past
12 months for PsA, and 71% were evaluated by
a rheumatologist at some point since their
diagnosis. Moreover, they were followed
specifically for PsA by different types of
physicians: rheumatologist (37%), primary care
provider (28%), and dermatologist (24%).
When analyzed by country, the proportions of
patients seen by rheumatologists for PsA ranged
from 26% in Germany to 53% in Italy and
Spain, and the proportions of patients seen by
dermatologists for PsA ranged from 13% in the
UK to 46% in Germany. Those patients who had
not visited an HCP in the past 12 months
reported that they did not believe an HCP
could help (30%), their symptoms were not bad
enough (30%), symptoms were absent (20%),
current treatment was working (7%), and cost- or
insurance-related issues were a factor (5%).
Current Treatment
More than half of the patients with PsA (59%)
reported that they were receiving no treatment
or topical therapy only and were not receiving
any systemic medication for their joint disease.
Overall, the proportions of patients with PsA
who reported current treatment were 31% for
topical therapy only, 19% for conventional oral
therapy, 14% for biologic therapy, and 8% for
the combination of oral and biologic therapy.
Fig. 3 Impact of PsA on patients’ ability to function and work productively. aProportion of patients who responded with
yes; all other responses represent the proportion of patients reporting ‘‘a lot’’ or ‘‘some’’ impact of PsA. PsA psoriatic arthritis
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Although these treatment rates were low for
patients with PsA, they were higher than the
treatment rates reported by patients with
psoriasis, of whom only 5% were receiving
conventional oral therapy [disease-modifying
antirheumatic drugs (DMARDs)] and 3% were
receiving biologic therapy at the time of the
survey [22].
Conventional oral therapies that patients
with PsA (n = 196) reported receiving included
methotrexate (69%), cyclosporine (6%),
soriatane (3%), fumaric acid (2%),
sulfasalazine/sulfazine (2%), celecoxib (1%),
folic acid (1%), prednisone (1%), and other
(14%). Injectable medications that patients
with PsA (n = 160) reported receiving included
adalimumab (35%), etanercept (34%),
infliximab (11%), ustekinumab (6%),
methotrexate (5%), golimumab (4%),
certolizumab (3%), alefacept (1%), and other
(2%).
Treatment Burden
Conventional Oral Therapy (DMARDs)
More than 50% of patients who had received
oral DMARDs found it to be burdensome, with
one-third of patients reporting that the
therapies were very or moderately
burdensome. The most common reason
patients found oral DMARDs burdensome was
side effects; other reasons included the need for
laboratory monitoring (Fig. 4a). Methotrexate
was the oral DMARD most commonly reported
as current therapy (n = 100), and 34% of
patients reported it as ‘‘very burdensome.’’ The
most common reasons patients found
methotrexate burdensome were side effects
(69%) and need for laboratory monitoring
(26%). The most common reasons patients
discontinued conventional oral therapy were
lack or loss of effectiveness and lack of
tolerability (Fig. 4b).
Biologic Therapy
Among patients who received
injectable biologic therapy, 54% found it to be
burdensome, with nearly one-third reporting
that these medications were very or moderately
burdensome. The most common reasons
patients with PsA found biologic therapy
burdensome were side effects (25.8%), fear of
injections (22.7%), and inconvenience (9.1%;
Fig. 4c). Adalimumab and etanercept were the
injectable biologics most commonly reported as
current therapy. The most common reasons
patients with PsA discontinued biologic therapy
included lack or loss of effectiveness and cost or
insurance issues (Fig. 4d).
Overall, 64% of patients with PsA expressed
concern about the health risks associated with
long-term therapy, and 90% of patients with
PsA felt there was a need for better therapies for
psoriasis and PsA.
DISCUSSION
The MAPP survey is the largest multinational
probability survey of patients with psoriasis and
PsA to date [22, 23, 34]. PsA was reported in 21%
of the overall MAPP patient population, which
is generally consistent with published
prevalence estimates [4, 12, 16, 25, 28].
PsA was likely present, but undiagnosed in
a proportion of psoriasis patients. In the
global MAPP findings for psoriasis patients
without a diagnosis of PsA (n = 2714), 44%
reported pain or soreness in any joint, 16%
reported symptoms resembling enthesitis, and
26% reported symptoms resembling dactylitis
[22]. Although a number of conditions may
be associated with joint pain, previous studies
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have shown that a high proportion of
patients have undiagnosed PsA [2, 14, 28].
This could partially be related to the
differential diagnosis of PsA; in the physician
portion of the MAPP survey, dermatologists
cited the greatest challenge in managing
patients with PsA was differentiating PsA
from other arthritic diseases, while
rheumatologists felt the greatest challenge in
managing patients with PsA was the delay in
referral to their practice.
Patients with PsA experience a substantial
burden of disease [3, 4, 24, 29, 32, 33]. More
than half of the patients with PsA participating
in the MAPP survey reported their disease as
severe, compared with 27% of patients with
psoriasis. A large proportion of patients with
PsA reported pain or soreness in more than four
Fig. 4 The top ﬁve
burdens associated
with and reasons for
discontinuation of
conventional oral
therapy (a, b) and
biologic therapy (c, d)
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joints. Although patients may have
overestimated or underestimated the number
of involved joints, the HAQ-8 results did
confirm an increased impairment in physical
function in these patients compared with the
overall population of patients with PsA. The
physical impact of PsA was greater in patients
with symptoms of enthesitis and/or dactylitis.
In addition, physical function in patients with
PsA was affected by the extent of psoriasis, as
measured by palm count, with more severe
disability reported in patients with greater palm
counts. PsA also impacted productivity and
functionality, with 20–30% of patients
reporting that PsA affected their ability to
work full time, choose a career, and get or
keep a job. These findings are consistent with
the published literature [4, 24, 29, 32, 33] and
highlight the substantially greater impact of
joint disease on patients’ physical function and
the added burden of PsA on psoriasis patients.
Symptoms resembling enthesitis (i.e., pain/
swelling of heel) were reported by 31% of
patients, and symptoms resembling dactylitis
(i.e., ‘‘sausage’’ digits) were reported by 45% of
patients. Enthesitis and dactylitis, important
distinguishing features of PsA in many patients,
are associated with more severe disease; both
can be difficult to treat and can lead to disability
[5, 13, 31]. Approximately twice as many
patients with PsA (21%) had nail involvement
compared with patients with psoriasis alone
(11%), and 44% of patients with PsA reported
scalp involvement; however, overall these rates
are lower than those previously reported [8, 17,
18, 21, 26]. The presence of skin disease in these
areas has been found to have a disproportionate
effect on QoL and is often difficult to treat, with
limited effective treatment options [7, 9, 19,
21]. Lastly, co-morbidities, including
unspecified arthritis, hypertension, depression,
diabetes, and heart disease, were commonly
reported by patients with PsA, as was obesity.
This finding is consistent with prior reports of a
higher prevalence of cardiovascular disease and
associated risk factors, such as diabetes and
other chronic diseases, in patients with PsA
compared with psoriasis patients or matched
controls in the community [4, 6, 11, 15]. The
multiple co-morbidities, often present in a
single patient, complicate the selection of
therapeutic agents due to safety concerns and
create challenges in the assessment of the
functional impact of PsA.
Patients diagnosed with PsA were more likely
to be treated compared with patients with
psoriasis only [22]; however, many patients
with PsA remain untreated or undertreated.
Among patients with PsA, 42% reported
currently receiving systemic treatment
[conventional oral (19%) or biologic (22%)];
this rate of systemic treatment is far lower than
the 97% of patients with PsA reported to have
been prescribed a systemic treatment
[conventional oral (63%) or biologic (33%)] by
rheumatologists who participated in the MAPP
survey [34]. The majority of dermatologists
(65%) also reported prescribing systemic
treatment. Interestingly, the most common
reason patients with PsA did not seek
treatment by an HCP in the previous
12 months was that they did not think it
would help, which suggests that education
regarding the availability of effective
treatments is needed. Approximately 30% of
patients participating in the MAPP survey had
not seen a rheumatologist for their PsA; just
over one-third indicated that their
rheumatologist was the HCP they saw most
often for their PsA, while about one-quarter saw
their primary care provider or their
dermatologist. Some of these differences may
represent variations in health-care delivery and
access to specialists across the countries
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surveyed. However, these results underscore the
need for timely diagnosis in patients with PsA
and ensure their appropriate treatment and/or
referral to a specialist. Treatment differences
between patients and physicians may also
reflect disparities between written prescriptions
and prescriptions that are filled and taken by
patients. Thus, it is important for physicians to
discuss patient concerns about medications,
improve patient adherence, and, in turn,
improve clinical responses.
As with any survey, the MAPP survey is
limited by the ability of patients to recall
information, the nature of the questions, and
the interpretation of the questions. The sample
included a higher proportion of females than in
the general population, suggesting potential
recruitment bias or over-reporting of this
population. Because the survey relies on
patient self-reporting, it is possible that
patients had a misperception of PsA and the
symptoms they experienced, such as nail
involvement or the more complicated
enthesitis and dactylitis. In addition, because
this survey was blinded, there was no way to
re-contact patients for clarification of answers.
The survey did not include a control group, and
information on treatments was limited to drug
therapy classes. Few questions were asked about
specific treatment options; thus, no meaningful
comparison among treatments can be made.
The survey also did not account for differences
in country, ethnicity, age, and direct and
indirect costs of health care. Further
limitations of this study include the
uncertainty about the specific diagnoses and
the treatments received. Patients may have
misunderstood the diagnosis given by their
HCP, or their HCP may have made an
incorrect diagnosis. The effect of this
uncertainty on the results is unknown, but it
does mean that the results should be interpreted
with caution. On the whole, the clinical data
obtained are consistent with what is known
about PsA; however, the high proportion of
females in the PsA group suggests that this
sample may not be representative of the
population as a whole.
CONCLUSIONS
The MAPP survey results underscore the
substantial disease burden associated with PsA
and the significant impact on physical function.
Survey results suggest undertreatment of PsA as
well as a high rate of treatment burden.
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